KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Short term Debt (2019 - 2025)

Castle Biosciences' Short term Debt history spans 5 years, with the latest figure at $417000.0 for Q4 2025.

  • For Q4 2025, Short term Debt rose 50.0% year-over-year to $417000.0; the TTM value through Dec 2025 reached $417000.0, up 50.0%, while the annual FY2025 figure was $417000.0, 50.0% up from the prior year.
  • Short term Debt for Q4 2025 was $417000.0 at Castle Biosciences, down from $1.9 million in the prior quarter.
  • Across five years, Short term Debt topped out at $20.8 million in Q1 2022 and bottomed at $278000.0 in Q4 2024.
  • The 3-year median for Short term Debt is $1.1 million (2025), against an average of $4.9 million.
  • The largest YoY upside for Short term Debt was 50.0% in 2025 against a maximum downside of 50.0% in 2025.
  • A 3-year view of Short term Debt shows it stood at $20.8 million in 2022, then plummeted by 98.67% to $278000.0 in 2024, then soared by 50.0% to $417000.0 in 2025.
  • Per Business Quant, the three most recent readings for CSTL's Short term Debt are $417000.0 (Q4 2025), $1.9 million (Q2 2025), and $1.1 million (Q1 2025).